Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, De Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G and GIMEMA Working Party on Chronic Myeloid:
Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemiaImatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia
Blood
2004; 104: 4245-4251
Subjects: CML
Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlachn T, Schoch C:
Clonal aberrations in chronic myeloid leukemia independent to the Philadelphia aberration during treatment with imatinib or interferon
Leukemia
19 (2005) 460-463
Subjects: CML
Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb H-J, Löffler H, Pralle H, Queisser W, Hehlmann R and the German CML-Study Group:
Gender aspects in chronic myeloid leukaemia: long-term results from randomized studies
Leukemia
2005; 19: 984-989
Subjects: CML
Berger U, Engelich G, Reiter A, Hochhaus A, Hehlmann R:
The German CML Study Group: Imatinib and beyond-the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
Ann Hematol
83:258-264 (2005)
Subjects: CML
Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R:
German CML-Study Group: Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
Leukemia
19:984-9 (2005)
Subjects: CML
Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A:
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Leukemia
2005;19:1774-82
Subjects: CML
Crossman LC, Mori M, Hsieh YC, Lange T, Paschka P, Harrington CA, Krohn K, Niederwieser DW, Hehlmann R, Hochhaus A, Druker BJ, Deininger MWN::
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures
Haematologica
90:459-464 (2005)
Subjects: CML
Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R, Seifarth W:
Induction of centrosome and chromosome aberrations by imatinib in vitro
Leukemia
2005;19:1573-8
Subjects: CML
Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, Seifarth W:
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability
Leukemia
2005; 19:1192-7
Subjects: CML
Gratwohl A:
Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation
Haematologica
2005 Feb;90(2):151
Subjects: SCT
Gratwohl A, Rosti G, Baccarani M.:
Does early stem-cell transplantation have a role in chronic myeloid leukaemia?
Lancet Oncol
2005; 6: 721-723
Subjects: CML
Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R.:
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Blood
2012;119(25):5963-71.
[pmid:22508936]
Subjects: CML
Hasford J, Pfirrmann M, Hochhaus A:
How long will chronic myeloid leukaemia patients treated with imatinib mesylate live?
Leukemia
2005; 19: 497-499
Subjects: Epidemiology
Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J:
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukaemia treated with interferon-alpha
Haematologica
2005; 90: 335-340
Subjects: Epidemiology
Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhauser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T:
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study
J Clin Oncol
2005;23:7583-93
Subjects: CML
Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM:
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
Leukemia
2005, 19:990-997
Subjects: SCT
Kruger S, Emig M, Lohse P, Ehninger G, Hochhaus A, Schackert HK:
The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians
Leukemia
2005 Nov 24; Reply to Inokuchi et al. Leukemia. 2005 Nov 24
Subjects: CML
Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A:
4.5 year follow up of response and resistance in 300 patients with BCR-ABL positive leukemias treated with imatinib in a single center
Cancer
103 (2005) 1659-1669
Subjects: CML
Lucy C. Crossman, Motomi Mori, Yi-Ching Hsieh, Thoralf Lange, Peter Paschka, Christina A. Harrington, Knut Krohn, Dietger W. Niederwieser, Rüdiger Hehlmann, Andreas Hochhaus, Brian J. Druker, Michael W.N. Deininger:
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures
Haematologica
90 (2005) 459-464
Subjects: CML
Martinelli g, Cilloni D, Rondoni M, Messa F, Ottaviani E, Gottardi E, Piccaluga PP, Malagola M, Soverini S, Merante S, Alimena G, Bosi C, De Vivo A, Rosti G, Giuliana E, Pane F, Izzo B, Testoni N, Paolini S, Rancati F, Bassan R, Mecucci C, Baccarani M, Saglio G:
Imatinib mesylate can induce molecular complete remission in idiopathic hypereosinophilic syndrome (HES). A phase II multicentric Italian Clinical Trial
Blood
2005; 106 (11): abstract 375
Subjects: CML
Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC:
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
Cancer
Res 65:2662-7 (2005)
Subjects: AML
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, De Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M:
ABL mutation in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to Imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia
J Clin Oncol
2005; 23: 4100-4109
Subjects: CML
Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, Fuchs R, Schmitt-Gräff A, Hehlmann R, Cross NC, Reiter A:
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
Leukemia
19:1005-9 (2005)
Subjects: CML
About us
The objective of the European LeukemiaNet is to integrate the leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia-related research and health care and cure.